Determining Lipid Content in Stool After Alpha-cyclodextrin

NCT ID: NCT03002168

Last Updated: 2017-11-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-01-20
• Study Completion Date: 2017-06-05

Brief Summary

The Investigator hypothesizes that the currently used dose of dietary ingredient alpha-cyclodextrin (α-CD) will result in greater loss of dietary fat in the stool compared with placebo. The proposed studies will address the degree to which α-CD increases dietary fat loss.

The Investigator will conduct the study and analyze the samples at Mayo Clinic in Rochester, Minnesota.

Detailed Description

This is a single-center, randomized, double-blind, placebo controlled, two-way crossover trial in healthy volunteers. The primary objective is to determine the fat losses in stool associated with alpha-cyclodextrin use as compared to placebo using a radiotracer. The study design will include two treatment periods, assigned in random order:

• Treatment 1 consists of subjects receiving α-CD and a meal containing the fatty acid radiotracers
• Treatment 2 consists of subjects receiving placebo and a meal containing the fatty acid radiotracers

All subjects randomized to receive α-CD will orally ingest two tablets containing α-CD, or placebo, with a standardized liquid breakfast (100 µ Ci of [3H]triolein and 20 µ Ci of [14C] tripalmitin). The tablets will be consumed with 150 ml of still (uncarbonated) water immediately prior to consuming each meal.

Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient following the breakfast meal containing the radiotracers. During this time the participants will undergo a meal fatty acid metabolism study, through hourly blood and fecal sampling, to assess meal fatty acid oxidation and storage.

The participants will then undergo a further ≥ 14 day washout period before crossing over to the alternate treatment, where all evaluations will be repeated.

Conditions

Healthy Participants

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Alpha-cyclodextrin

Two 1 gram Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets (6 grams) per day for the first two consecutive days of active treatment period. Triolein radiolabeled with 100 microcuries of 3\^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14\^Carbon given orally with liquid breakfast meal.

Group Type: ACTIVE_COMPARATOR

Alpha-cyclodextrin

Intervention Type: DIETARY_SUPPLEMENT

Alpha-cyclodextrin is approved by the Food and Drug Administration as a dietary ingredient.

Triolein radiolabeled with 100 microcuries of 3^Hydrogen

Intervention Type: RADIATION

A MicroCurie (µCi) is a measure of radioactivity.

Tripalmitin radiolabeled with 20 microcuries of 14^Carbon

Intervention Type: RADIATION

A MicroCurie (µCi) is a measure of radioactivity.

Placebo

Two Placebo Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets per day for the first two consecutive days of placebo treatment period.Triolein radiolabeled with 100 microcuries of 3\^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14\^Carbon given orally with liquid breakfast meal.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

Placebo tablets identical in appearance to the active comparator

Triolein radiolabeled with 100 microcuries of 3^Hydrogen

Intervention Type: RADIATION

A MicroCurie (µCi) is a measure of radioactivity.

Tripalmitin radiolabeled with 20 microcuries of 14^Carbon

Intervention Type: RADIATION

A MicroCurie (µCi) is a measure of radioactivity.

Interventions

Alpha-cyclodextrin

Alpha-cyclodextrin is approved by the Food and Drug Administration as a dietary ingredient.

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Placebo tablets identical in appearance to the active comparator

Intervention Type: DIETARY_SUPPLEMENT

Triolein radiolabeled with 100 microcuries of 3^Hydrogen

A MicroCurie (µCi) is a measure of radioactivity.

Intervention Type: RADIATION

Tripalmitin radiolabeled with 20 microcuries of 14^Carbon

A MicroCurie (µCi) is a measure of radioactivity.

Intervention Type: RADIATION

Other Intervention Names

FBCx; Calorease

Eligibility Criteria

Inclusion Criteria

• Healthy weight stable individuals (defined as a Body Mass Index (BMI) of ≥18.5 and <27, and stable for at least the preceding two months from Screening).
• Not pregnant, and if of childbearing potential, agrees to use adequate birth control (hormonal or barrier method of birth control or abstinence) prior to study entry and during the trial and agrees not to donate sperm or ova, for the duration of the study
• Subjects ≥18 and ≤60 years of age at screening
• Consistent regular bowel movement (defined as between 3 times a day, to 1 time per day)
• Provide Informed Consent
• Willing and able to complete study procedures within the study timelines
• Adequate renal function: serum creatinine less than 1.5 x Upper Limit of Normal (ULN)
• Adequate liver function: serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST) and serum glutamic pyruvic transaminase/alanine aminotransferase (SGPT/ALT) ≤ 2 × ULN and serum bilirubin ≤ 1.5 × ULN, unless Gilbert's syndrome has previously been confirmed for the subject
• Adequate bone marrow function: white blood cells (WBCs) ≥ 3,000/mm^3, absolute neutrophil count (ANC) ≥ 1,500/mm^3, hemoglobin ≥ 9 gram/deciLiter, and platelets ≥ 100,000/mm^3

Exclusion Criteria

• Evidence of chronic pancreatitis
• Evidence of irritable bowel syndrome (medical or self-diagnosed)
• Previous gallbladder surgery
• Use of enemas and/or suppositories within 30 days of Screening
• Consuming ≥ 375 mg of caffeine per day (equivalent to 5 serves of 1 oz. restaurant style espresso per day)
• History of febrile illness within 5 days prior to Screening
• Evidence or history of substance or alcohol abuse
• History of major depression, bipolar disorder, or schizophrenia (per DSM4 criteria; Diagnostic and Statistical Manual of Mental Disorders)
• Current use of prescription or non-prescription weight loss products (≥ 2 week washout period is required to become eligible)
• Smoking ≥ 20 cigarettes (~one pack) per week
• Significant dietary restrictions (incl. vegan, vegetarian diets and any subject not prepared to consume any of the standardized food/s)
• Evidence of an active eating disorder (incl. anorexia nervosa, bulimia, and/or obsessive compulsive disorders)
• Use of other investigational agent(s at the time of enrollment, or within 30 days or five half-lives of enrollment, whichever is longer
• Pregnant or lactating
• Current use of any medication known to affect gut motility
• History of malignancy, treated or untreated, within the past five years, with the exception of non-melanoma skin cancer and cervical carcinoma in situ
• A known history of hypersensitivity to any of the α-CD ingredients
• Any other health condition that would preclude participation in the study in the judgment of the principal investigator

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

SFI Research

INDUSTRY

Sponsor Role: collaborator

Mayo Clinic

OTHER

Sponsor Role: lead

Responsible Party

Michael D. Jensen

MD, Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Michael D Jensen, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Countries

United States

References

Lytle KA, Harteneck DA, Noble AM, Jensen MD. The Soluble Fiber alpha-Cyclodextrin Does Not Increase the Fecal Losses of Dietary Fat in Adults-A Double-Blind, Randomized, Placebo-Controlled, Crossover Trial. J Nutr. 2018 Sep 1;148(9):1421-1425. doi: 10.1093/jn/nxy135.

Reference Type: DERIVED

PMID: 30107536 (View on PubMed)

Other Identifiers

16-005006

Identifier Type: -

Identifier Source: org_study_id